MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Retained Earnings 2011-2026 | PCRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -206 M | -107 M | -149 M | -212 M | - | -399 M | -388 M | -389 M | -346 M | -308 M | -310 M | -296 M | -233 M | -180 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -107 M | -399 M | -271 M |
Quarterly Retained Earnings Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -201 M | -206 M | -202 M | -206 M | -222 M | -78.9 M | -97.8 M | -107 M | -132 M | -143 M | -168 M | -149 M | -139 M | - | -158 M | -212 M | -207 M | -224 M | -244 M | -254 M | -254 M | -254 M | -254 M | -399 M | -399 M | -399 M | -399 M | -388 M | -388 M | -388 M | -388 M | -389 M | -389 M | -389 M | -389 M | -346 M | -346 M | -346 M | -346 M | -308 M | -308 M | -308 M | -308 M | -310 M | -310 M | -310 M | -310 M | -296 M | -296 M | -296 M | -296 M | -233 M | -233 M | -233 M | -233 M | -180 M | -180 M | -180 M | -180 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -78.9 M | -399 M | -267 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-472 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.31 | - | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.06 B | $ 2.53 | 0.4 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.02 | -0.37 % | $ 411 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.19 | 4.59 % | $ 44.9 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.0 | -2.15 % | $ 1.82 B | Canada |
 |
Harrow Health
HROW
|
-157 M | $ 35.17 | 3.43 % | $ 1.29 B | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
-661 M | $ 4.61 | -1.5 % | $ 297 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 1.05 | 2.45 % | $ 24.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | $ 6.07 | 3.58 % | $ 240 M | USA |
 |
Solid Biosciences
SLDB
|
-958 M | $ 6.9 | -3.43 % | $ 604 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.32 | -9.02 % | $ 2.88 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.37 | 0.37 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 6.41 | -0.62 % | $ 3.96 B | Canada |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Veru
VERU
|
-295 M | $ 2.33 | 1.3 % | $ 314 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 13.45 | 1.17 % | $ 16.1 B | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.88 | 0.25 % | $ 43.9 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.78 | 2.52 % | $ 3.36 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.35 | 1.73 % | $ 24.5 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
-3.68 B | $ 9.6 | 0.31 % | $ 1.33 B | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 0.95 | -1.52 % | $ 102 M | Canada |
 |
Assertio Holdings
ASRT
|
-703 M | $ 15.92 | 13.68 % | $ 102 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |